Ipsen S.A. (IPN.PA) stock analysis
In our weekly check, Ipsen S.A. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 18 pass, warnings: 3, red flags: 4.
About Ipsen S.A.
Ipsen S.A. is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in France, listed on PAR as IPN.PA.
What our checks show for IPN.PA
Red flags
- The net margin fell by 11.4 points over 5 years, to 12.1%: the company keeps less of each sale as profit.
- The gross margin fell by 13.5 points, to 70.6%: costs are rising faster than prices.
- The stock has fallen as much as 76% from a peak. Would you have held through that?
- Recovering from its deepest fall took about 5.9 years.
Warning signs
- Earnings per share fell 9.3% a year over the last 3 years.
- Net profit fell 11.8% a year over the last 3 years.
- Thinly traded (about 106 thousand shares a day): buying and selling can move the price.
Strengths
- Debt is low: 0.2x equity.
- Operating profit covers interest 23.1 times over.
- Operating cash flow is 2.56x net profit: the profit arrives as real cash.
- Analysts expect earnings per share to grow about 34.9% a year over the next years.
- Analysts expect the net margin to improve by 12.3 points from today's 12.1%.
- Free cash flow is 28.1% of revenue: cash for dividends, buybacks or growth.
Similar companies
ELAN · VTRS · ALKS · LNTH · AMRX · ZTS
Questions
What grade does Ipsen S.A. (IPN.PA) have?
In our weekly check, Ipsen S.A. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 18 pass, warnings: 3, red flags: 4. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of IPN.PA stock?
This week's biggest flags for Ipsen S.A.: Margins falling, Gross margin falling, Deep past fall. In total 7 of 25 checks show a warning or a red flag.
What does Ipsen S.A. do?
Ipsen S.A. is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in France, listed on PAR as IPN.PA.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-10-24
Open the full analysis